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Although pituitary adenomas (PAs) are commonly classified as benign lesions, their clinical course is not always benign, and studies have confirmed 
that patients harboring a secreting adenoma have a reduced 
life expectancy, particularly those affected by adrenocor-
ticotropic hormone (ACTH)– or growth hormone (GH)–
secreting adenoma.15,24,29,38,46 For such patients, endocri-
nological remission through gross-total resection (GTR) 
is the goal. Similarly, GTR is recommended for nonfunc-
tioning pituitary adenomas (NFAs) requiring surgery, since 
subtotal resection (STR) and adenoma remnants after sur-
gery have been repeatedly shown to represent a risk factor 
AbbreviAtioNs ACTH = adrenocorticotropic hormone; EOR = extent of resection; GH = growth hormone; GTR = gross-total resection; iMRI = intraoperative MRI; NFA = 
nonfunctioning pituitary adenoma; PA = pituitary adenoma; STR = subtotal resection; t = targeted; TSS = transsphenoidal surgery; TVDT = tumor volume doubling time.
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obJective The aim of this study was to quantitatively assess the role of intraoperative high-field 3-T MRI (3T-iMRI) in 
improving the gross-total resection (GTR) rate and the extent of resection (EOR) in endoscopic transsphenoidal surgery 
(TSS) for pituitary adenomas.
methods Radiological and clinical data from a prospective database were retrospectively analyzed. Volumetric mea-
surements of adenoma volumes pre-, intraoperatively, and 3 months postoperatively were performed in a consecutive 
series of patients who had undergone endoscopic TSS. The quantitative contribution of 3T-iMRI was measured as a 
percentage of the additional rate of GTR and of the EOR achieved after 3T-iMRI.
results The cohort consisted of 50 patients (51 operations) harboring 33 nonfunctioning and 18 functioning pituitary 
adenomas. Mean adenoma diameter and volume were 21.1 mm (range 5–47 mm) and 5.23 cm3 (range 0.09–22.14 cm3), 
respectively. According to Knosp’s classification, 10 cases were Grade 0; 8, Grade 1; 17, Grade 2; 12, Grade 3; and 4, 
Grade 4. Gross-total resection was the surgical goal (targeted [t]GTR) in 34 of 51 operations and was initially achieved 
in 16 (47%) of 34 at 3T-iMRI and in 30 (88%) of 34 cases after further resection. In this subgroup, the EOR increased 
from 91% at 3T-iMRI to 99% at the 3-month MRI (p < 0.05). In the 17 cases in which subtotal resection (STR) had been 
planned (tSTR), the EOR increased from 79% to 86% (p < 0.05) and GTR could be achieved in 1 case. Intrasellar rem-
nants were present in 20 of 51 procedures at 3T-iMRI and in only 5 (10%) of 51 procedures after further resection (me-
dian volume 0.15 cm3). Overall, the use of 3T-iMRI led to further resection in 27 (53%) of 51 procedures and permitted 
GTR in 15 (56%) of these 27 procedures; thus, the GTR rate in the entire cohort increased from 31% (16 of 51) to 61% 
(31 of 51) and the EOR increased from 87% to 95% (p < 0.05).
coNclusioNs The use of high-definition 3T-iMRI allowed precise visualization and quantification of adenoma rem-
nant volume. It helped to increase GTR and EOR rates in both tGTR and tSTR patient groups. Moreover, it helped to 
achieve low rates of intrasellar remnants. These data support the use of 3T-iMRI to achieve maximal, safe adenoma 
resection.
http://thejns.org/doi/abs/10.3171/2015.12.FOCUS15564
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for adenoma regrowth8,20,31,35 and possibly a reduced life 
expectancy.10 Therefore, intraoperative technical aids to 
increase the extent of resection (EOR) of PAs continue to 
attract a lot of attention in the neurosurgical and endocri-
nological communities.
Surgical techniques for PAs include the sublabial sub-
mucosal, the transseptal, and the endonasal approaches. 
In 1992 the endonasal endoscopic approach was first de-
scribed26 and gained wide popularity in the neurosurgical 
community because of its increased intraoperative view-
ing capacity and possibly improved GTR rate. Contrast-
enhanced intraoperative MRI (iMRI), first introduced by 
Black et al. in 1994,6 has been increasingly used in pitu-
itary surgery based on the assumption that it would im-
prove GTR rates.14,17,21,33,34,36,37,41,47,48 Moreover, it has been 
stated that iMRI may be helpful even in patients in whom 
GTR is not feasible.34 In these patients, iMRI could still 
help to extend the tumor resection beyond the capabilities 
of microsurgical or endoscopic techniques alone. Lastly, 
some authors have suggested that iMRI can reduce the 
incidence of intrasellar remnants.11 Intrasellar adenoma 
remnants are amenable to complete and safe resection as 
long as they can be correctly detected. The rate of intra-
sellar adenoma remnants may, therefore, be considered a 
reliable surrogate marker of the surgical result.
All reports on the adjunctive benefit of iMRI have so 
far based their claims on qualitative analysis alone and 
not on quantitative volumetric measurement data. Fur-
thermore, imaging of the sellar region is highly dependent 
on the technical performance of the scanner. Only a few 
reports have analyzed the added value of high-field iMRI, 
and even fewer reports have described the value of 3-T 
intraoperative MRI (3T-iMRI) in PA surgery. The aims 
of the present study were 1) to present the surgical results 
obtained with 3T-iMRI in a consecutive series of patients 
who underwent endoscopic transsphenoidal surgery (TSS) 
for PA, and 2) to report quantitative volumetric measure-
ments of the EOR for both the whole adenoma and, more 
specifically, the intrasellar adenoma component.
methods
patients
Clinical and radiological data on patients who under-
went surgery for PA between July 2013 and June 2015 at 
the Department of Neurosurgery, University Hospital of 
Zürich, were prospectively collected and retrospectively 
analyzed. All patients were treated according to the same 
PA protocol, and all had a complete endocrinological as-
sessment preoperatively and immediately postoperatively 
as well as 6 weeks and 3 months postoperatively. Ophthal-
mological assessment, including testing of visual function 
and visual field, was routinely performed before and after 
surgery. Patient data were treated according to the ethical 
standards of the Declaration of Helsinki as approved by 
our institutional committee (Cantonal Ethics Committee 
Zürich).
Neuroimaging and volumetric measurement
All patients underwent preoperative, intraoperative, 
and 3-month postoperative volumetric contrast-enhanced 
3T-MRI (Siemens 3-T Skyra VD13 with a NORAS MRI 
Products intraoperative 8-channel head coil). Adenoma 
morphology was graded according to the Knosp27 and 
Hardy classifications.52 Source DICOM images of the vol-
umetric sequences of each 3-T MR image (pre-, intra-, and 
postoperative) were uploaded onto iPlan software for volu-
metric measurements (iPlan Cranial, BrainLab) for each 
patient. Each adenoma was manually contoured on source 
images to allow subsequent 3D rendering and volumetric 
measurement through the software (Fig. 1). Extent of re-
section was measured on both intraoperative and 3-month 
postoperative MRI and was calculated as follows: 1) final 
EOR = percentage of residual tumor at the 3-month MRI 
compared with tumor on preoperative MRI; 2) endoscopic 
EOR = percentage of residual tumor at the 3T-iMRI com-
pared with tumor on preoperative MRI; and 3) iMRI EOR 
= percentage of residual tumor at the postoperative MRI 
compared with tumor on 3T-iMRI, to measure the con-
tribution of 3T-iMRI in improving the EOR. Mean dif-
ferences between EORs among groups were tested with 
the paired-sampled Student t-test (or ANOVA for multiple 
comparisons). The null hypothesis was that there was no 
difference in the average EOR before (endoscopic EOR) 
and after 3T-iMR (final EOR). Correlations among con-
tinuous variables were studied with the Pearson test. For 
descriptive statistics, the cohort was divided into 2 groups: 
targeted (t)GTR, in which GTR was the goal of surgery; 
and targeted subtotal resection (tSTR), in which GTR was 
deemed not possible because of adenoma extension, and 
therefore only STR was the goal. The decision about the 
surgical goal for each adenoma was made based on the 
invasiveness pattern and was registered in the database; 
adenomas classified as Knosp Grade 0, 1, or 2 were con-
sidered for GTR. 
surgical procedure and intraoperative imaging
The 3T-iMRI suite consists of a 2-room concept in 
which the patient is moved and the MR scanner remains 
fixed. The operating theater is connected to the MRI suite 
by a sliding door. All surgical procedures were performed 
by the same surgical team consisting of a neurosurgeon 
(L.R.) and an otorhinolaryngologist (D.H.) and follow-
ing the same surgical protocol described as follows. A 
standard endonasal transsphenoidal endoscopic (Storz) 
approach with the common 3-hand technique was per-
formed; a mononostril approach was used in 90% of the 
patients. The surgical goal (tGTR vs tSTR) was decided 
before surgery, as described above. After the neurosurgeon 
declared that the resection was complete or felt that further 
resection was not safe enough, the surgery was interrupted 
and 3T-iMRI was performed. When 3T-iMRI confirmed 
GTR, the surgery was completed with a sellar reconstruc-
tion. When the 3T-iMRI showed residual tumor, further 
endoscopic inspection was done and additional resection 
was performed if feasible. Intrasellar remnants were al-
ways considered to be amenable to further resection. Only 
1 3T-iMRI session was performed for each patient.
results
Fifty consecutive patients (23 females and 27 males, 
mean age of 52 years [range 21–83 years]) underwent 51 
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operations in the study period. Thirty-three patients (66%) 
harbored NFA and 17 (34%) had functioning adenoma; 
9 patients (10 operations) had a GH-secreting adenoma, 
7 had treatment-refractory prolactinoma, and 1 had an 
ACTH-secreting adenoma (Table 1). Average volume of 
the surgically treated adenomas was 5.23 cm3 (range 0.09–
22.14 cm3, median volume 3.10 cm3), and mean adenoma 
diameter was 21.1 mm (range 5–47 mm). Average volume 
for the NFAs was 6.60 cm3 (range 0.56–22.14 cm3, median 
4.60 cm3), whereas for the functioning adenomas it was 
2.72 cm3 (range 0.09–20.60 cm3, median 0.92 cm3).
resection results 
Thirty-four PAs were in the tGTR group and 17 in 
the tSTR group (Fig. 2). For the entire cohort, GTR was 
achieved in 31 of 51 operations, corresponding to a GTR 
rate of 61%, and the average EOR was 95% at the 3-month 
postoperative MRI. More specifically, in the tGTR group, 
GTR was indeed achieved in 30 (88%) of 34 operations. 
Gross-total resection was also achieved in 1 of the 17 
tSTRs. Average overall EOR was 99% and 86% for the 
tGTR and tSTR groups, respectively, at 3 months after 
surgery. Surgical complications were as follows. Minor 
infections occurred in 2 patients (pneumonia in 1 and 
sphenoidal sinusitis in 1), whereas 1 patient (2%) had men-
ingitis as a consequence of a CSF leak. Cerebrospinal fluid 
leak requiring surgery occurred in 3 patients (6%), and en-
docrine function deteriorated in 5 patients (hypothyroid-
ism [1], permanent diabetes insipidus [1], new hypocorti-
solism [2], hypogonadism [1]). Of the 17 patients with a 
Fig. 1. Volumetric segmentation of adenoma volume on the preoperative (A), intraoperative (b), and postoperative (c) MRI.
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tAble 1. summary of volumetric resection results and remnant locations before and after 3t-imr
Case 
No. 
Intended 
Resection
Knosp 
Grade
Hardy 
Grade
EOR at 
3T-iMR
Remnant Location 
at 3T-iMR
EOR at 
3-Mo MRI
Remnant 
Location at 3-Mo 
MRI
New Endocrine 
Deficit
Endocrine 
Remission
Adenoma 
Type
1 tGTR 1 BII 0.85 IS, SS 0.96 IS No NA NFA
2 tGTR 2 AII 0.70 IS 1.00 — No Yes GH
3 tGTR 2 BIII 1.00 — 1.00 — Yes NA NFA
4 tGTR 0 AII 1.00 — 1.00 — No No PRL
5 tGTR 0 0I 1.00 — 1.00 — No Yes GH
6 tGTR 2 BII 0.95 IS 1.00 — No NA NFA
7 tGTR 0 0I 1.00 — 1.00 — No Yes PRL
8 tGTR 2 AII 1.00 — 1.00 — No NA NFA
9 tGTR 2 AIV 1.00 — 1.00 — No NA NFA
10 tGTR 2 AII 1.00 — 1.00 — No NA NFA
11 tGTR 0 0I 1.00 — 1.00 — No Yes PRL
12 tGTR 2 AII 1.00 — 1.00 — No NA NFA
13 tGTR 0 0I 0.53 IS 0.83 IS No No PRL
14 tGTR 0 0I 1.00 — 1.00 — No Yes PRL
15 tGTR 2 0II 1.00 SS* 1.00 — No NA NFA
16 tGTR 2 AII 1.00 — 1.00 — No NA NFA
17 tGTR 1 AII 1.00 — 1.00 — No Yes GH
18 tGTR 1 BIV 0.88 IS, CS 0.97 IS No NA NFA
19 tGTR 0 0I 0.80 IS 1.00 — No Yes GH
20 tGTR 2 AIV 0.94 SS 1.00 — No NA NFA
21 tGTR 1 CII 0.96 IS 1.00 — No NA NFA
22 tGTR 2 CIII 0.92 IS, SS 1.00 — No NA NFA
23 tGTR 0 AIII 0.74 IS, SS 1.00 — No NA NFA
24 tGTR 1 AIII 0.97 IS 1.00 — No NA NFA
25 tGTR 0 0I 1.00 — 1.00 — Yes Yes ACTH
26 tGTR 1 BII 0.98 IS 1.00 — No NA NFA
27 tGTR 1 0I 0.88 IS 1.00 — No Yes PRL
28 tGTR 2 AIV 1.00 — 1.00 — No NA NFA
29 tGTR 2 BIV 0.96 SS 1.00 — No NA NFA
30 tGTR 2 BIV 0.95 IS 1.00 — No No GH
31 tGTR 3 NA 0.20 CS 1.00 — No NA NFA
32 tGTR 2 AII 0.96 SS 1.00 — Yes NA NFA
33 tGTR 1 0II 1.00 — 1.00 — No No GH
34 tGTR 2 CIV 0.94 IS, SS 0.99 IS No NA NFA
35 tSTR 4 CIV 0.63 CS, SS 0.86 CS, SS No NA NFA
36 tSTR 3 AIII 0.76 IS, CS, SS 0.94 CS No NA NFA
37 tSTR 3 AII 0.91 IS, CS 0.99 CS Yes Yes GH
38 tSTR 3 AIV 0.89 IS, CS 0.91 CS No NA NFA
39 tSTR 3 CIV 0.84 CS, SS 0.84 CS, SS No NA NFA
40 tSTR 4 DIV 0.50 CS, RS 0.50 CS, RS No NA NFA
41 tSTR 3 DIV 0.24 CS, SS 0.24 CS, SS No NA NFA
42 tSTR 3 BII 0.94 IS, SS 0.97 SS No NA NFA
43 tSTR 3 AII 0.95 —† 0.95 CS No NA NFA
44 tSTR 3 AIV 0.90 CS 0.90 CS No No GH
45 tSTR 3 BII 0.96 SS 1.00 — No NA NFA
46 tSTR 2 BIV 0.89 IS 0.89 IS Yes No PRL
47 tSTR 4 BIV 0.94 CS, SS 0.94 CS, SS No NA NFA
CONTINUED ON PAGE 5 »
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functioning adenoma, GTR was achieved in 11 and com-
plete endocrinological remissions occurred in 10 of them 
(GH-secreting adenoma in 5, prolactin-secreting adenoma 
in 4, and ACTH-secreting adenoma in 1). No patient ex-
perienced deterioration of the visual field or visual acuity.
Influence of iMRI on GTR and EOR
Details on how the use of 3T-iMRI influenced the 
course of surgery are reported in Fig. 2. In the tGTR group, 
GTR increased from 16 (47%) of 34 to 30 (88%) of 34 and 
EOR from 91% at 3T-iMRI to 99% at the 3-month MRI 
(p < 0.05). In the tSTR group, GTR could be achieved in 
1 (6%) of 17 cases after 3T-iMRI. More noticeably, EOR 
increased in the tSTR group from 79% to 86% (p < 0.05). 
Overall, the use of 3T-iMRI led to further resection in 27 
(53%) of 51 cases, and GTR was achieved in 15 (56%) of 
these 27 cases. Thus, the GTR rate for the entire cohort 
increased from 31% (16 of 51 cases) to 61% (31 of 51 cases) 
and the EOR increased from 87% to 95% (p < 0.05). The 
amount of adjunctive EOR due to 3T-iMR did not show 
any relationship with adenoma functional activity (p = 
0.76), Knosp classification (p = 0.48), Hardy classification 
(p = 0.36), initial tumor volume (p = 0.23), or adenoma 
diameter (p = 0.51).
There were 1 false-positive and 1 false-negative find-
ings. In 1 patient (Case 43), no remnants could be seen at 
3T-iMRI; therefore, no further resection was undertaken. 
However, a small residual tumor (0.19 cm3) was detected 
in the left cavernous sinus at 3-month postoperative MRI. 
In another patient (Case 15), a small suprasellar remnant 
adenoma was suspected on 3T-iMRI, but it could not be 
confirmed either intraoperatively, despite further inspec-
tion, or at the 3-month postoperative MRI.
location of Adenoma remnants
Detailed description of the location of adenoma rem-
nants is provided in Table 1. Overall, adenoma remnants 
were seen in 36 cases at the 3T-iMRI. Intrasellar adenoma 
remnants were detected at 3T-iMRI in 20 cases (39%) ei-
ther alone or in combination with an adenoma remnant in 
other locations (suprasellar, cavernous sinus, retrosellar). 
At the 3-month postoperative MRI follow-up, intrasellar 
remnants were visible in only 5 patients (10%), resulting in 
a 90% GTR rate (46 of 51 cases) of the intrasellar adenoma 
in the entire cohort. The difference in the number of ade-
noma remnants between 3T-iMRI and 3-month postopera-
tive MRI was statistically significant (chi-square = 0.007). 
The volumes of the 5 intrasellar remnants were always tiny 
and averaged 0.21 cm3 (median 0.15 cm3, range 0.03–0.63 
cm3). In the remaining 15 cases with residual adenoma at 
the 3-month follow-up, remnants were in the cavernous si-
nus alone in 8, the cavernous sinus and suprasellar cisterns 
in 4, and the cavernous sinus and retrosellar region in 1. 
Purely suprasellar remnants were visible in 2 cases.
discussion
resection results
Since its introduction in 1994, endoscopy has been in-
creasingly used for transsphenoidal resection of PA with 
excellent results. Reported GTR rates range between 
44%44 and 88%.12 In series adopting endoscopy and iMRI, 
GTR rates achieved at the iMRI have been reported to be 
much lower, ranging from as low as 34% and 41%7,19,48 to 
as high as 62%.3 Indeed, a literature review suggests that 
groups adopting intraoperative imaging tend to have rela-
tively lower rates of initial GTR before performing iMRI 
than groups who do not use any intraoperative imaging. 
We thus performed a PubMed and Scopus search (search 
terms “intraoperative,” “MR,” “pituitary”) and selected 
those studies expressly reporting the number of patients 
harboring a tumor remnant at iMRI. From the 24 studies 
selected,1–3,7,14,16,17,19,22,28,32–34,36,37,40,41,43,45,47,48,50,51,53 we pooled 
the GTR data at the moment of iMRI. The average ini-
tial GTR rate was 51%, which compares poorly to rates 
achieved in both pure endoscopic and pure microsurgi-
cal series as reported in a recent meta-analysis (79% and 
65%, respectively13). However, after pooling the final GTR 
rate of all the above-mentioned iMRI studies, we calcu-
lated a GTR rate of 73%. These data are comparable to 
and eventually in line with the best GTR achievable with 
endoscopy and microsurgery alone. Our GTR rates, 61% 
in the whole cohort and 88% in tGTR group, are in line 
and even compare favorably with rates in the literature if 
we consider only the tGTR group.
The use of iMRI for pituitary surgery is the subject 
of animated debate in the neurosurgical community not 
lastly given its high acquisition, installation, and operation 
costs and prolonged operation times when used. Moreover, 
several authors continue to express skepticism toward its 
effectiveness and note—mainly in commentaries to iMRI 
papers (for example, see Powell in Paternó et al.,37 Kelly in 
» CONTINUED FROM PAGE 4
tAble 1. summary of volumetric resection results and remnant locations before and after 3t-imr
Case 
No. 
Intended 
Resection
Knosp 
Grade
Hardy 
Grade
EOR at 
3T-iMR
Remnant Location 
at 3T-iMR
EOR at 
3-Mo MRI
Remnant 
Location at 3-Mo 
MRI
New Endocrine 
Deficit
Endocrine 
Remission
Adenoma 
Type
48 tSTR 3 AII 0.53 IS, CS 0.70 CS No No GH
49 tSTR 0 CIII 0.75 SS 0.98 SS Lost Lost NFA
50 tSTR 3 CIV 0.74 CS, SS 0.96 CS No NA NFA
51 tSTR 4 BIV 0.97 CS 0.97 CS No No GH
CS = cavernous sinus; IS = intrasellar; NA = not applicable; PRL = prolactin; RS = retrosellar; SS = suprasellar.
* False positive.
† False negative.
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Schwartz et al.,43 Barnett in Gerlach et al.,19 and Mayberg in 
Wu et al.53)—that the use of iMRI biases the surgeon who, 
knowing that he or she will perform iMRI, would tend to 
be less aggressive in the pre-iMRI phase of the surgery 
than he or she would if the iMRI were unavailable. Given 
our experience, we tend to agree with this line of thinking. 
Furthermore, Powell39 stated that iMRI would simply show 
predictable remnants, which although rendered visible by 
iMRI are not resectable. This would explain the similar-
ity of the GTR rates achieved among the different surgical 
techniques—microsurgery and endoscopy, with or without 
iMRI.
It is difficult to make a meaningful comparison of 
GTR rates among heterogeneous patient series in which 
the percentage of patients with different surgical goals 
can vary (tGTR vs tSTR), and often outcome assessment 
(low-field vs high-field MRI) can also vary considerably. 
Still, most authors have reported that iMRI increases the 
EOR in adenoma surgery, especially for the tSTR group 
of patients.4,5,33,34,41 This suggests that although GTR rates 
appear similar among the different series, regardless of the 
technique adopted, the EOR is more extensive with the use 
of iMRI. Nevertheless, a quantitative study analyzing vol-
umetric measurements of both EOR and volume remnants 
after 3T-iMRI has not been published so far.
Volumetric Quantification of the Role of 3T-iMRI
Residual adenoma has been reported as a risk factor 
for regrowth in several studies.4,8,10,18,20,30 In a retrospective 
study on NFAs in 2008, Chang and coworkers10 found a 
recurrence rate of 10% in a cohort of 663 patients with a 
median follow-up of 8.4 years. Predictive factors for recur-
rence in that study were invasion of the cavernous sinus 
and subtotal resection without adjuvant radiotherapy. No 
predictive volumetric threshold was reported. According 
to Tanaka et al.49 and Honegger et al.,25 recurrent adeno-
mas show mostly an exponential growth pattern. However, 
tumor volume doubling time (TVDT) can vary signifi-
cantly between cases, with a younger age being a possi-
bly relevant risk factor.49 The MIB-1 index also seems to 
inversely correlate with TVDT.25,49 Whether an increase 
in the EOR plays a clinically relevant role in subtotally 
resected adenomas has not been established, however. 
Specifically, it is not known if stepwise incremental EOR 
values for adenomas correlate with incremental progres-
sion-free survival or whether the absolute residual volume 
or the relative residual volume is the prognostic factor. The 
answer, we hope, will come from large observational volu-
metric studies with long-term follow-ups. Similar stud-
ies are currently lacking in the literature, although some 
authors, particularly in radiosurgical series, have recently 
started to routinely assess the volumes of PAs and mea-
sure outcome in terms of EOR.11,23,31 Even though Class I 
evidence is lacking, we believe that in patients undergoing 
STR, the residual adenoma volume may be a prognostic 
factor, especially in young patients and in adenomas with 
Fig. 2. Schematic of the impact of 3T-iMR in pituitary endoscopic surgery. CS = cavernous sinus; IS = intrasellar; Rest = remnant; 
RS = retrosellar; SS = suprasellar; 3T-ioMR = 3-T intraoperative MR.
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high MIB-1 indexes. Therefore, maximal safe resection 
should be the surgical goal, always aiming for the smallest 
residual volume without adding any surgical or endocrino-
logical morbidity, as in the strategy increasingly adopted 
for the treatment of gliomas.42 It is debatable, however, if 
removing additional tumor volume compensates for the 
potential risk of the higher morbidity associated with fur-
ther surgical manipulation and with the prolonged surgical 
times due to the use of iMRI. This topic remains open for 
discussion. As a matter of fact, there is no clear evidence 
in the literature indicating that the use of iMRI in pituitary 
surgery leads to additional morbidity. It is known, as a gen-
eral rule, that a longer surgery is associated with a higher 
incidence of complications, particularly if the surgery 
lasts more than 2 hours.9 In our study, however, we did 
not have any complications characteristically attributable 
to prolonged surgery, such as respiratory failure or deep 
venous thrombosis. It is also difficult to ascertain whether 
the postoperative occurrence of a new deficit is due to the 
surgical manipulation before or after the iMRI (this par-
ticularly concerns endocrinological deficits). In our series, 
no complication can be unequivocally attributed to fur-
ther resection after 3T-iMRI, which is in line with findings 
in the available literature. Of the 3 patients who required 
surgical revision for rhinoliquorrhea, 1 had no intraopera-
tive evidence of CSF loss, whereas the other 2 already had 
some CSF loss before 3T-iMRI was performed. Of the 5 
patients with new postoperative endocrinological deficits, 
only 2 had further resection after 3T-iMRI.
Three-tesla iMRI allows very precise intraoperative as-
sessment of the EOR and gives immediate feedback to the 
surgeon. In other words, it allows the surgeon not only to 
determine the presence or absence of a remnant and its 
precise location, but also to measure the residual volume. 
The surgeon can therefore adapt his or her surgical strat-
egy to precise information and better evaluate the EOR 
that can be achieved and the risk the patient will incur by 
adopting a more aggressive strategy with further resec-
tion. The use of 3T-iMRI significantly helped in reaching 
this target and achieving the increase of 7% and 8% in the 
EOR, as reported in our tSTR and tGTR groups, respec-
tively.
location of Adenoma remnant
The high-definition imaging quality achieved with 3T-
iMRI is such that residual adenoma parts can be finely de-
picted not only in the suprasellar space, as is the case with 
low-field iMRI, but also in the intra- and parasellar areas 
(Figs. 1 and 3). As stated above and confirmed by our data, 
accurate visualization of parasellar, particularly intracav-
ernous, remnants does not usually imply that a GTR will 
be achieved. On the contrary, intrasellar remnants are 
mostly amenable to complete resection. In our opinion, for 
the intrasellar remnants in particular, improved intraopera-
tive visualization with 3T-iMR is important so that resect-
able remnants are not overlooked. Indeed our data tend to 
support this belief since we had 21 (41%) of 51 intrasellar 
remnants detected with 3T-iMR, as compared with only 
5 (10%) of 51 at the 3-month MRI follow-up. These intra-
sellar remnants were small, averaging 0.21 cm3. Similarly, 
Coburger et al.11 found a significantly lower incidence of 
intrasellar remnants in patients undergoing adenoma re-
moval with the help of 1.5-T MRI compared with patients 
undergoing standard microsurgery (18% vs 57%). The 
very low rate of intrasellar remnants (< 10%) in our study 
tends to indicate that high-definition visualization of an 
intrasellar remnant with 3T-iMRI offers the opportunity 
to improve resection. The endoscope allows for accurate 
exploration of the sella and visualization of its contents. 
However, it does not allow one to “look behind,” and in 
some cases adenoma tissue, even if in the field of view 
of the endoscope, cannot be reliably distinguished from 
pituitary parenchyma. Three-tesla iMRI helps not only to 
look behind, but also to discriminate between healthy pi-
tuitary and pathological adenoma tissue, offering a highly 
detailed anatomical view of the sella and its contents.
Fig. 3. Pre-, intra-, and postoperative imaging in 2 different cases. The intra- and parasellar compartments are finely depicted 
in both patients. upper row: The intraoperative imaging clearly shows a small intrasellar rest on the right side, which could be 
further removed although not completely. lower row: Some residual intrasellar remnants can be easily identified on the right side 
at the medial wall of the cavernous sinus. These were completely removed.
c. serra et al.
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conclusions
With the use of 3T-iMRI, we achieved a GTR rate of 
61% in the whole cohort and 88% in the tGTR group. 
The incorporation of 3T-iMRI helped to precisely deter-
mine the amount and location of residual tissue and to in-
crease the EOR in both patient groups, tGTR (from 91% 
to 99%) and tSTR (from 79% to 86%). Moreover, it helped 
to achieve a very low rate of intrasellar remnants (10%) 
in the entire cohort, showing that an intrasellar adenoma 
component is amenable to complete resection if it is cor-
rectly diagnosed during surgery. These data support the 
use of 3T-iMRI to help achieve maximal, safe adenoma 
resection.
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